Package Leaflet: Information for the Patient
Vocabria 30 mg Film-Coated Tablets
cabotegravir
This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will include information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Vocabria tablets contain cabotegravir as the active substance. Cabotegravir belongs to a group of antiretroviral medicines called integrase inhibitors (INI).
Vocabria tablets are used to treat HIV (Human Immunodeficiency Virus) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg), who are also taking another antiretroviral medicine called rilpivirina and whose HIV-1 infection is under control.
Vocabria tablets do not cure HIV infection; they keep the amount of virus in your body at a low level. This helps to keep the number of CD4+ cells in your blood at a high level. CD4+ cells are a type of white blood cell that is important for helping your body to fight infections.
Your doctor may advise you to take Vocabria tablets before you are given Vocabria injections for the first time.
If you are already being given Vocabria injections, but you are unable to receive your injection, your doctor may also recommend that you take Vocabria tablets instead, until you can receive your injection again.
Vocabria tablets are always taken in combination with another antiretroviral medicine called rilpivirina tabletsto treat HIV infection. Vocabria and rilpivirina tablets will replace your current antiretroviral medicines. See the package leaflet for rilpivirina for more information about this medicine.
Do not take Vocabria tablets
If you think this applies to you, tell your doctor.
Warnings and precautions
Severe skin reaction
Very rare cases of severe skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with Vocabria. If you notice any of the symptoms related to these severe skin reactions, stop taking Vocabria and seek medical attention immediately.
Read the informationin section 4 of this leaflet (“Possible side effects”).
Allergic reaction
Vocabria contains cabotegravir, which is an integrase inhibitor. Integrase inhibitors, including cabotegravir, may cause a severe allergic reaction known as hypersensitivity reaction. You need to know what the important signs and symptoms are to look out for while you are taking Vocabria.
Read the informationin section 4 of this leaflet.
Liver problems including hepatitis B and/or C
Tell your doctor if you have or have had liver problems, including hepatitis B and/or C. Your doctor will assess the severity of your liver disease before deciding if you can take Vocabria.
Be aware of important symptoms
Some people who take medicines for HIV infection develop other conditions, which can be serious.
You need to know what the important signs and symptoms are to look out for while you are being treated with Vocabria. These include:
Read the informationin section 4 of this leaflet (“Possible side effects”).
If you have symptoms of infection or liver damage:
Tell your doctor immediately.Do not take other medicines for infection unless your doctor advises you to.
Children and adolescents
This medicine must not be used in children under 12 years of age or adolescents weighing less than 35 kg, as it has not been studied in these patients.
Other medicines and Vocabria tablets
Tell your doctor if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription.
Vocabria must not be takenwith other medicines (see ‘Do not take Vocabria tablets’ above in section 2).
Some medicines may affect how Vocabria worksor increase the chance of you having side effects. Vocabria may also affect how other medicines work.
Tell your doctorif you are taking any of the medicines on the following list:
Do not take these medicinesin the 2 hours before taking Vocabria or until at least 4 hours after taking it.
Tell your doctoror pharmacist if you are taking any of these. Your doctor may decide that you need extra checks.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby:
Ask your doctorfor advice before taking Vocabria tablets.
Pregnancy
Breast-feeding
It is not recommendedthat HIV-infected women breast-feed their babies because HIV infection can be passed to the baby through breast milk.
It is not knownwhether the components of Vocabria tablets can pass into breast milk.
If you are breast-feeding or think you may want to breast-feed, talk to your doctor as soon as possible.
Driving and using machines
Vocabria may make you feel dizzyand have other side effects that make you less alert.
Do not drive or use machinesunless you are sure that you are not affected.
Important information about some of the ingredients of Vocabria
If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, which is essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Vocabria tablets must always be taken with another HIV medicine (rilpivirina tablets). You must also carefully follow the instructions for rilpivirina. The package leaflet is provided in the rilpivirina pack.
Dosing schedule of Vocabria tablets before the injection schedule
Which medicine | When | ||
Month 1(at least 28 days) | Month 2 (after 1 month of tablets) | Month 3 onwards | |
Vocabria | 30 mg tablet once a day | 600 mg injection | 400 mg injection every month |
Rilpivirina | 25 mg tablet once a day | 900 mg injection | 600 mg injection every month |
Dosing schedule of Vocabria tablets before the every 2 months injection schedule
Which medicine | When | ||
Month 1(at least 28 days) | Month 2 and Month 3 (after 1 month of tablets) | Month 5 onwards | |
Vocabria | 30 mg tablet once a day | 600 mg injection | 600 mg injection every 2 months |
Rilpivirina | 25 mg tablet once a day | 900 mg injection | 900 mg injection every 2 months |
When you start treatmentwith Vocabria, you and your doctor may decide to start treatment with Vocabria tablets or go straight to Vocabria injections. If you decide to start with the tablets, your doctor will tell you:
The first month of Vocabria and rilpivirina tablets is called the oral lead-in period. This will allow your doctor to check if it is suitable for you to switch to the injections.
How to take the tablets
Vocabria tablets should be swallowed with a little water.
Vocabria can be taken with or without food. However, when Vocabria is taken at the same time as rilpivirina, both tablets should be taken with food.
If you are unable to receive your Vocabria injection
If you think you will not be able to receive your Vocabria injection, your doctor may recommend that you take Vocabria tablets or another treatment for HIV instead, until you can receive your injection again.
Antacid medicines
Antacids, to treat indigestionand stomach acid, may stop Vocabria tablets from being absorbed into your body and make them less effective.
Do not take an antacidin the 2 hours before taking Vocabria or until at least 4 hours after taking it. Talk to your doctor for more information about how to take medicines to reduce stomach acid (antacids) with Vocabria tablets.
If you take more Vocabria than you should
If you take too many Vocabria tablets, contact your doctor or pharmacist for advice. If possible, show them the pack of Vocabria tablets.
If you forget to take Vocabria
If it is less than 12 hours since you were supposed to take Vocabria, take the missed tablet as soon as possible. If it is more than 12 hours since you were supposed to take Vocabria, miss that dose and take the next dose as usual.
Do not take a double doseto make up for a forgotten dose.
If you vomit less than 4 hours after taking Vocabria, take another tablet. If you vomit more than 4 hours after taking Vocabria, you do not need to take another tablet until your next scheduled dose.
Do not stop taking Vocabria without your doctor’s advice.
Keep taking Vocabria for as long as your doctor recommends. Do not stop unless your doctor advises you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Stop taking Vocabria and seek immediate medical attentionif you notice any of the following symptoms:
Allergic Reactions
Vocabria contains cabotegravir, which is an integrase inhibitor. Integrase inhibitors, including cabotegravir, can cause a severe allergic reaction known as a hypersensitivity reaction. These hypersensitivity reactions are uncommon (they can affect up to 1 in 100people).
If you experience any of the following symptoms:
See your doctor immediately. Your doctor may consider it necessary to perform tests to check your liver, kidneys, or blood and may advise you to stop taking Vocabria.
Very Common Adverse Effects
These can affect more than 1 in 10people:
Common Adverse Effects
These can affect up to 1 in 10people:
Uncommon Adverse Effects
These can affect up to 1 in 100people:
Other Adverse Effects that May Appear in Blood Tests
Other Possible Adverse Effects
People taking HIV treatment with Vocabria and rilpivirine may have other adverse effects.
Pancreatitis
If you have severe abdominal pain (stomach), this may be due to pancreas inflammation (pancreatitis).
Tell your doctor, especially if the pain spreads and worsens.
Symptoms of Infection and Inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more prone to developing severe infections (opportunistic infections). When they start treatment, the immune system strengthens, so the body begins to fight these infections.
Symptoms of infection and inflammation can develop, caused by:
The symptoms of autoimmune disorders can appear many months after starting to take medications to treat HIV infection.
The symptoms may include:
If you have any symptoms of infection or inflammationor if you notice any of the above symptoms:
Tell your doctor immediately.Do not take other medications for the infection without consulting your doctor first.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the box and bottle after CAD. The expiration date is the last day of the month indicated.
This medicine does not require any special storage temperature.
Medicines should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Vocabria Composition
The other ingredients are:
Tablet core
Lactose monohydrate
Microcrystalline cellulose (E460)
Hypromellose (E464)
Sodium carboxymethyl starch
Magnesium stearate
Tablet coating
Hypromellose (E464)
Titanium dioxide (E171)
Macrogol (E1521)
Product Appearance and Package Contents
Vocabria film-coated tablets are white, oval, and engraved with 'SV CTV' on one side.
The film-coated tablets are presented in child-resistant closed bottles.
Each bottle contains 30 film-coated tablets.
Marketing Authorization Holder
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Netherlands
Manufacturer
Glaxo Wellcome, S.A.
Avda. Extremadura, 3
09400 Aranda de Duero (Burgos)
Spain
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel: + 32 (0) 10 85 65 00 | Lietuva ViiV Healthcare BV Tel: + 370 80000334 |
ViiV Healthcare BV Te?.: + 359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel: + 32 (0) 10 85 65 00 |
Ceská republika GlaxoSmithKline, s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Magyarország ViiV Healthcare BV Tel.: + 36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: + 356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Nederland ViiV Healthcare BV Tel: + 31 (0) 33 2081199 |
Eesti ViiV Healthcare BV Tel: + 372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλάδα GlaxoSmithKline Μονοπρóσωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 17 69 69 Infomed@viivhealthcare.com | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com |
Hrvatska ViiV Healthcare BV Tel: + 385 800787089 | România ViiV Healthcare BV Tel: + 40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: + 386 80688869 |
Ísland Vistor ehf. Sími: +354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: + 421 800500589 |
Italia ViiV Healthcare S.r.l Tel: + 39 (0)45 7741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κύπρος ViiV Healthcare BV Τηλ: + 357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvija ViiV Healthcare BV Tel: + 371 80205045 |
Date of Last Revision of this Leaflet:<{MM/AAAA}.
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu